Hyundai Bio Expands Production Line for COVID-19 Oral Antiviral 'CP-COV03'

Dongkook Pharmaceutical and Consignment Production Promotion Business Agreement Signed
Consultations Ongoing for Consignment Production of Anticancer Drug Formulations Including Politaxel

[Asia Economy Reporter Lee Gwan-joo] Hyundai Bio has begun expanding its production line to ensure the stable supply of the oral COVID-19 treatment 'CP-COV03.'

On the 9th, Hyundai Bio announced that it had signed a memorandum of understanding (MOU) with Dongkook Pharmaceutical to enable the production and supply of CP-COV03, an oral antiviral drug for COVID-19.

This agreement was made to quickly and stably respond to global demand if CP-COV03 receives emergency use authorization from the government. Dongkook Pharmaceutical, in consultation with Hyundai Bio, can produce finished products or supply raw materials together with Yooyoung Pharmaceutical, the primary contract manufacturing organization (CMO) for CP-COV03. Previously, Hyundai Bio signed a contract with Yooyoung Pharmaceutical last year for the contract manufacturing and supply of CP-COV03.

Hyundai Bio plans to increase the number of patients according to the relevant criteria and conduct integrated Phase 2a and 2b clinical trials, aiming to apply for emergency use authorization by next month once the health authorities approve the Phase 2 clinical trial plan for CP-COV03.

A Hyundai Bio official said, "Once CP-COV03 receives emergency use authorization and is officially launched, a production network capable of promptly responding to both domestic and global demand is necessary. We signed an agreement with Dongkook Pharmaceutical to expand the production line to ensure the stable supply of CP-COV03."

Additionally, Hyundai Bio plans to discuss entrusting Dongkook Pharmaceutical with the development of clinical formulations and the production of finished products for several anticancer drugs developed by the company, including the 'pain-free' anticancer drug Polytaxel, which is currently preparing for global clinical trials.

Hyundai Bio intends to apply for and conduct clinical trials for Polytaxel targeting pancreatic cancer in Australia and for several other cancers, including breast cancer, in South Korea during the first half of this year.

This content was produced with the assistance of AI translation services.